The HPV 9-10 Trial: Early Initiation of HPV Vaccination

Description

Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In this study, we will examine in a randomized trial whether earlier initiation of the vaccine at age 9-10 years will result in less parental refusal and higher rates of full vaccination at younger ages, before early sexual activity begins.

Conditions

HPV

Study Overview

Study Details

Study overview

Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In this study, we will examine in a randomized trial whether earlier initiation of the vaccine at age 9-10 years will result in less parental refusal and higher rates of full vaccination at younger ages, before early sexual activity begins.

The HPV 9-10 Trial: Early Initiation of HPV Vaccination

The HPV 9-10 Trial: Early Initiation of HPV Vaccination

Condition
HPV
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California at Los Angeles, Los Angeles, California, United States, 90095

Aurora

University of Colorado, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Practices in Metro Denver, Colorado and Metro Los Angeles, California (specifically UCLA medical clinics and clinics affiliated with Children's Hospital of Orange County)
  • * Practices that have at least 60% of providers agree to participate
  • * Practices do not currently recommend HPV at 9-10 years.
  • * Practice must have at least 100 eligible patients age 9-13 years
  • * Practices with less than 100 eligible patients age 9-13 years
  • * Practices currently routinely recommend HPV vaccine at 9-10 years.
  • * Practices where less than 60% of providers agree to participate in the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Allison Kempe, MD, MPH, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2025-04-01